BCL2L1 and cancer: Challenging HCT116 cells with ABT-737 (targeting BCL-2, BCL-XL and BCL-W), WEHI-539 (targeting BCL-XL) and ABT-199 (targeting BCL-2) only marginally killed cancer cells (Fig. 1a)15–18.